2 news · updated 15 hours ago

Drugmaker duty case

2026-10-22

Gilead to Acquire PepStar's Inflammation Drug Program in $1.28 Billion Deal

Gilead Sciences agreed to acquire PepStar Therapeutics' oral inflammation drug program for $1.275 billion in cash. The deal adds HCXT-2001, an experimental treatment targeting the IL-23 pathway for in

reuters · 2026-10-22 13:12 UTC

2026-05-06

California's Highest Court to Consider Whether Drugmakers Have 'Duty to Innovate'

The California Supreme Court will hear arguments on whether drugmakers face a legal 'duty to innovate,' specifically in a Gilead Sciences case involving HIV medication development delays. A ruling cou

reuters · 2026-05-06 03:03 UTC

Drugmaker duty case

Gilead to Acquire PepStar's Inflammation Drug Program in $1.28 Billion Deal

California's Highest Court to Consider Whether Drugmakers Have 'Duty to Innovate'

Media coverage (2)

Related topics